NEW YORK, Sept. 02, 2022 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is notifying investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Diagnostics” or ” the Company “) CODX and certain of its officers on behalf of all persons and entities that purchased or otherwise acquired Co-Diagnostics Securities between May 12, 2022 and August 11, 2022 inclusive (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website: www.bgandg.com/codx.
This class action seeks damages against the defendants for alleged violations of federal securities laws.
The lawsuit alleges that the defendants made false and/or misleading statements and failed to disclose material adverse facts to the market. On August 11, 2022, Co-Dx shocked investors when the company issued a press release and filed a report with the Securities and Exchange Commission, disclosing its financial results for the quarter ended June 30, 2022. The company reported revenue of $5.0 million for the quarter ended June 30, 2022, compared to $27.4 million for the same period last year, a decrease of nearly 82%. The company attributed the decline primarily to lower demand for the Logix Smart™ COVID-19 test. As a result of this news, the price of Co-Dx common stock fell $1.98 per share, or 30.65%, to close at $4.48 per share on August 12, 2022.
A class action lawsuit has already been filed. If you would like to see a copy of the complaint, you can visit the firm’s website: www.bgandg.com/codx or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss at Co-Diagnostics, you have until October 17, 2022 to request that the court appoint you lead plaintiff. Your ability to participate in a recovery does not require you to serve as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC represents investors in…
